Cantor Fitzgerald reiterates Neutral rating on Pfizer stock By Investing.com

Cantor Fitzgerald reiterated a Neutral rating on Pfizer with a $27 price target, modestly above the current $26.18 share price. The firm’s meeting with Pfizer oncology management highlighted incremental PD-1xVEGF updates, including early ctDNA clearance data in SSGJ-707 showing about 37% of baseline patients cleared ctDNA by cycle 3. The broader article also noted Pfizer’s 6.57% dividend yield and recent pipeline/commercial updates, but nothing materially changing the near-term investment case.

Analysis

This read-through is more important for relative positioning in oncology than for Pfizer’s headline. The market is still rewarding any credible PD-1xVEGF signal, but the incremental nature of the disclosure means the near-term alpha is in data validation, not new information flow; that typically compresses follow-through unless the next readout shows clear biomarker enrichment. The ctDNA-clearing subset matters because it creates a plausible early surrogate for a small fraction of responders, which can steepen the probability-weighted value of the program without yet justifying a re-rate of the whole pipeline.

The second-order winner could be Rigel rather than Pfizer if the licensing economics are real and the asset can be repositioned into a larger commercial platform; smaller biotechs tend to gap on partner validation even when the press release looks mundane. That said, these situations often fade once investors realize the economics are back-ended and the development risk remains with the acquirer/partner structure. UBS and the other neutral calls suggest the sell-side is anchored to dividend support and capital return, not pipeline optionality, so upside in PFE is likely capped unless oncology data start to alter long-duration earnings assumptions.

The key risk is that enthusiasm for the class remains broader than the evidence base, especially if upcoming competitors show stronger ctDNA clearance or more durable PFS. If later cohorts fail to reproduce the early separation, the biomarker narrative can reverse quickly because the market has already started to ascribe more confidence to a surrogate that is still exploratory. Over the next 1-3 months, this is more likely to be a sentiment-trade than a fundamentals trade; over 6-12 months, the relevant catalyst is whether a Phase III readout can convert biomarker promise into a differentiated launch profile.

Key Decisions for Investors

• Prefer a relative-value long RIGL / short basket of large-cap pharma over the next 2-6 weeks: the partner-validation effect can reprice small-cap optionality faster than it can move Pfizer’s mature equity story; stop if the next clinical/financing update disappoints.
• Maintain or add to PFE only as a defensive income holding, not as a catalyst trade: 3-12 month horizon, with upside capped unless oncology data materially improve; use pullbacks toward the low-$26s to accumulate and trim into any relief rally.
• If seeking oncology beta, rotate into a basket of PD-1/VEGF-adjacent names rather than single-name PFE exposure: 1-3 month trade on sector momentum, with the risk that incremental data fails to differentiate the lead asset.
• Consider a call spread in PFE only for dividend-supported upside capture into the next catalyst window: limited premium outlay, but keep strikes conservative because the stock already sits near consensus targets.
• Set a downside alert on RIGL if licensing economics or milestone structure proves small: the upside is event-driven, but the stock can retrace quickly once the market normalizes the deal as non-transformational.